Multiple myeloma (MM), the second most common blood cancer in the United States, occurs at a much higher rate in veterans than in the general population. For U.S. veterans the burden of disease is shaped by a convergence of demographic, biologic and service-related risk factors.
Multiple myeloma (MM) occurs about twice as often in men as in women, but until recently the biologic and clinical drivers of that disparity have been poorly understood.
Multiple myeloma (MM) remains treatable but not curable; however, the therapeutic landscape has changed dramatically over the past decade.
Since 2022, the VA has recognized multiple myeloma (MM) as a presumptive condition for a growing number of veterans, significantly raising the hematological malignancy’s profile within the agency.